Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,821 total articles
InPlay Oil (IPOOF) is trading near $12.50 with bullish momentum indicators, a 6.4% yield and a market cap of ~$348M. For traders willing to accept commodity risk and OTC liquidity, a disciplined long swing trade captures upside to the 52-week high while collecting a monthly distribution and keeping downside manageable with a tight stop.
Mercedes-Benz ADR (MBGYY) looks set for upside over the next 180 trading days. The shares trade at a sub-1.0 P/B and a single-digit P/E while yielding ~5.6%. Technicals are oversold and recent corporate optionality (planned Daimler Truck stake sale) plus product wins in EVs support a rebound. This trade plan gives a clear entry at $14.25, a stop at…
BridgeBio (BBIO) has momentum you can trade: sustained survival benefit for Attruby plus multiple positive mid/late-stage readouts have pushed market expectations higher. The balance sheet and valuation are stretched, but a clear entry, stop and target give a defined risk-reward for a mid-term swing (about 45 trading days).
ServiceNow ($NOW) has been punished for near-term margin guidance and macro noise, but its Now Platform is uniquely positioned to be the enterprise "control tower" for AI-enabled workflows. At a market cap near $92B and free cash flow of about $4.6B, a tactical long into weakness with a $120 target and $80 stop offers an asymmetric risk/reward over…
Adobe is trading like a secular growth business knocked down by short-term AI concerns. At roughly $240, the stock offers a low-teens P/E, $10.3B in free cash flow and a newly announced $25B buyback — set up for a mid-term swing trade with defined risk.
ASML remains the linchpin of advanced chip manufacturing. Recent results and guidance show durable demand, but the stock now trades at a steep premium. This trade recommends a disciplined long with a mid-term horizon to capture further multiple expansion while protecting capital against macro, supply-chain, or demand hiccups.
Upstart (UPST) reported a major new product launch that management says set internal records for early adoption. The combination of that rollout, a compact market cap (~$3.0B), elevated short interest and constructive technicals creates a defined long trade: enter $30.00, stop $27.50, target $48.00 over a mid-term horizon (45 trading days). This is…
Adobe is trading near $243 after a pullback driven by AI disruption fears. With free cash flow north of $10.3B, a $25B buyback authorization, attractive P/E and P/FCF multiples, and meaningful enterprise momentum in AI partnerships, the setup favors a long trade with defined risk. Entry $243.57, stop $220.00, target $330.00 over a long-term horizon…
Materialise (MTLS) is a $310M market-cap provider of 3D printing software, medical devices, and manufacturing services. With the medical segment showing secular tailwinds (surgical simulation, custom orthotics, patient-specific devices) and a neutral-to-bullish technical setup, we see a high-probability swing trade. Entry $5.25, target $6.50 (mid-t…
Lemonade plunged to $57.47 on heavy volume after a broader growth-stock sell-off. Fundamentals — 30%+ premium growth, accelerating in-force premiums, and management guidance showing robust top-line expansion — argue for buying the dip. This is a tactical long: entry $57.47, stop $50.00, target $85.00, horizon mid term (45 trading days).
Talen Energy (TLN) has materially expanded its fleet through recent acquisitions and is funding additional capacity with $4.0 billion in senior notes. That capital-intensive growth raises leverage, but it also meaningfully lifts generation capacity and the company's ability to capture wholesale power and capacity revenues. For traders willing to ac…
Southern Company (SO) is executing a measured shift from legacy generation toward renewables and grid modernization backed by a $26.5 billion DOE loan. With a $105.6B market cap, a 3.1% yield and 25 years of dividend increases, SO offers income plus upside if the clean-energy transition accelerates. This trade targets a recovery above prior resista…
Xylem (XYL) is a cash-generative leader in water infrastructure, applied water and measurement solutions. At $114.77 the stock has pulled back to its 52-week low even as revenue and FCF remain healthy. With a conservative balance sheet (debt/equity 0.17), $910M of free cash flow and clear structural tailwinds - from municipal upgrades to data-cente…
Dorman Products (DORM) trades at a reasonable multiple given $75.7M of free cash flow, a $3.34B market cap and low leverage. Management changes and a steady pipeline of first-to-aftermarket parts reduce execution risk. I see an asymmetric mid-term trade ahead of Q1 earnings: buy into strength with a clear stop and a target near prior resistance.
Shell’s reported $16 billion ARC transaction tightens the landscape for high-quality upstream assets and supports a re-rating for low-cost natural gas producers. With crude trading above $100 and macro risk pushing energy real assets back into favor, Tourmaline stands out as a pragmatic trade: strong free-cash-flow potential, domestic LNG optionali…
Pulse Seismic should benefit from higher oil prices and an uptick in Western Canadian exploration activity. This trade seeks to capture a mid-term rebound driven by stronger seismic demand, with a clear entry at $2.40, target of $3.60 and a protective stop at $1.80.
AppLovin remains a top adtech growth name supported by AI-driven ad products and strong recent growth prints. The stock has pulled back from short-term overbought levels; technicals and short-interest dynamics favor a tactical long. This trade idea outlines a mid-term swing to capture continued monetization gains while limiting downside with a tigh…
Nucor (NUE) is trading near $222 after a year of volatility and operational execution that highlights the advantages of its mini-mill model and capital discipline. With a market cap around $50.6B, a manageable debt load (debt-to-equity ~0.34) and EPS of $7.63, the company looks set to convert cyclical upside into sustained shareholder returns. This…
Kiniksa (KNSA) just raised full-year Arcalyst guidance after Q1 revenue of $214M and is trading near a 52-week high. The earnings beat, strong free cash flow and an active clinical pipeline create a favorable setup for a long trade. This idea outlines an entry at current levels, a protective stop and a 180-trading-day target tied to continued uptak…
Stride’s platform issues appear to be fading and enrollment updates are broadly constructive. At roughly a $4.1B market cap and an EV/EBITDA near 7.2, the stock is priced for modest growth. We present a mid-term long trade that bets on re-rating as enrollment stabilizes and guidance holds.
Roivant's Genevant settlement with Moderna and a string of positive Phase 3 results for brepocitinib give the company both near-term optionality and a path to sustainable revenue. With $9.73 billion in reported cash, a market cap near $19.8 billion and a pipeline catalyst calendar through 2026, ROIV is a buy for patient, risk-tolerant investors tar…
Starbucks delivered a punchy Q2 with $9.5B in revenue and comps beating expectations. The market has been overly obsessed with headline multiples; underlying cash flow, margin recovery and restored U.S. traffic suggest upside in the next 45 trading days. This trade isolates momentum while protecting capital with a clear stop.
POET Technologies rocketed and then crashed after Marvell canceled orders tied to Celestial AI and multiple law firms opened investigations. At $6.51 and a ~$995M market cap, the company is now priced for a worst-case near-term outcome. That creates a tactical mid-term (45 trading days) long opportunity for disciplined traders who accept headline r…
Pollard Banknote is a small-cap, cash-generative printer of lottery and secure products. Recent margin compression appears cyclical and tied to temporarily elevated input and logistics costs plus mix shifts. With cost actions in place and a steady backlog of contracted work, the stock looks like a high-probability margin-recovery trade. This note l…
Connect Biopharma (CNTB) is a small-cap clinical-stage biotech whose IL-4Rα antibody rademikibart has shown efficacy in type 2 asthma. With presentations supporting lung function gains and reduced exacerbations, there's a plausible extension into an emergency/acute-exacerbation setting. At a market cap near $142M and enterprise value near $97M, thi…
